ArticleBMC complementary medicine and therapies2025
Changji'an formula alleviates visceral hypersensitivity of a post-inflammatory IBS-D mouse model via NGF/TrkA signaling pathway.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChangji'an Formula (CJAF) is an effective Chinese herbal prescription to treat irritable bowel syndrome with predominant diarrhea (IBS-D), which is derived from two famous classical prescription: Sijunzi decoction and Tong-Xie-Yao-Fang. However, the molecular mechanism has not been well defined. This study aims to illustrate the molecular mechanism of CJAF in the treatment of IBS-D.
methodsChemical components of CJAF were determined by ultrahigh performance liquid chromatography-quadrupole/orbitrap high resolution mass spectrometry (UPLC-Q-Orbitrap HRMS) and further verified by reference standards. IBS-D model was induced in C57BL/6J mice by a single edema with colonic infusion of 0.1 mL trinitrobenzene sulfonic acid (TNBS, 50 mg/mL) combined with 7 days of restraint stress, 2 h/d. The treatment group was given rifaximin (100 mg/kg) and high, moderate and low doses of CJAF by gavage for 7 days, respectively (n = 7). After administration, the main symptoms of IBS-D were tested, and behavioral tests were conducted using sucrose preference test and open field test. The colonic tissues of mice were obtained. Gene and protein expression of mast cell tryptase, nerve growth factor (NGF), tyrosine kinase receptor A (TrkA), phosphorylated TrkA, growth associated protein 43(GAP43) and neuro-specific enolase (NSE) were determined by RT-PCR, western blot and immunohistochemistry.
results36 compounds were identified by UPLC-Q-Orbitrap HRMS, and the determined components can be categorized into 7 chemical types, including 16 flavonoids, 7 triterpenoids, 4 alkaloids, 3 sesquiterpenoids, 2 monoterpene glycosides, 2 organic acids, 1 phenylpropanoids and 1 tannin. Animal experiment showed that the abdominal pain and diarrhea symptoms of IBS-D mice were alleviated by CJAF. The sucrose preference, total translocation distance and average velocity of movement in the open field test was upregulated. The mRNA and protein expression of mast cell marker tryptase, as well as NGF, phosphorylated TrkA, GAP43 and NSE in IBS-D mice colonic tissues were down-regulated by CJAF.
conclusionsCJAF could effectively alleviate abdominal pain and diarrhea symptoms of IBS-D by inhibiting the activation of colonic mast cells and the resultant activation of NGF/TrkA signal pathway. Therefore, CJAF affords a potential candidate for the treatment of IBS-D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.